Stoke Therapeutics STOK 深 滬
已收盤 08-08 16:00:00 美东时间
13.10
-0.150
-1.13%
華盛通- 最 高13.4846
- 今 開13.23
- 成交量 38.54万股
- 最 低 12.88
- 昨 收 13.25
- 總市值 7.15亿
- 52周最高 16.15
- 市盈率 靜 --
- 換手率 0.71%
- 52周最低 5.35
- 委 比 5.17%
- 總股本 5459.69万
- 歷史最高 71.58
- 量 比 0.83
- 振 幅 4.56%
- 歷史最低 3.35
- 每 手 1
- 風險率 4.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Nasdaq Composite falling around 100 points on ...
07-22 22:23
Jefferies Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $30
Jefferies analyst Andrew Tsai initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating and announces Price Target of $30.
07-18 19:50
BEWI ASA Completes Strategic Mergers with Unipol and STOK Emballage
Bewi ASA ( ($DE:5T0) ) just unveiled an update. BEWI ASA has completed the merg...
07-10 14:34
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
Biogen and Stoke Therapeutics announced positive data from an analysis supporting the Phase 3 zorevunersen dosing regimen for Dravet syndrome, showing improved cognition and behavior at Week 68. The findings contrast with natural history data and support the inclusion of key secondary endpoints in the Phase 3 EMPEROR study. Previously, zorevunersen demonstrated durable reductions in seizures and cognitive/behavioral improvements in Phase 1/2a and...
07-10 11:00
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $22 price target.
07-01 18:20
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
HC Wainwright & Co. Maintains Buy on Stoke Therapeutics, Lowers Price Target to $35
HC Wainwright & Co. analyst Andrew Fein maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and lowers the price target from $47 to $35.
05-15 01:51
美股牛股 | “AI妖股”MicroAlgo放量暴涨75%！特朗普会见零售巨头讨论关税影响
“AI妖股”重获资金关注！MicroAlgo放量暴涨75%；柯尔百货隔夜大涨超8%，特朗普会见多家零售巨头讨论关税影响>>
04-22 19:46
